Amyloid β induces interneuron-specific changes in the hippocampus of APPNL-F mice
暂无分享,去创建一个
I. Módy | T. Freund | T. Saido | Takashi Saito | Virág T. Takács | K. Sos | G. Nyiri | Zsuzsanna Bardóczi | Abel Major | Márton I. Mayer | Barnabas M Beres | Tamás Szeles | T. Saito | Márton I Mayer
[1] A. Srikiatkhachorn,et al. Altered activity in the nucleus raphe magnus underlies cortical hyperexcitability and facilitates trigeminal nociception in a rat model of medication overuse headache , 2019, BMC Neuroscience.
[2] A. Prochiantz,et al. Perineuronal nets in brain physiology and disease. , 2019, Seminars in cell & developmental biology.
[3] F. Edwards. A Unifying Hypothesis for Alzheimer’s Disease: From Plaques to Neurodegeneration , 2019, Trends in Neurosciences.
[4] Yan-Mei Huang,et al. Major Clinical Trials Failed the Amyloid Hypothesis of Alzheimer's Disease , 2019, Journal of the American Geriatrics Society.
[5] T. Saido,et al. Amyloid-β plaque formation and reactive gliosis are required for induction of cognitive deficits in App knock-in mouse models of Alzheimer’s disease , 2019, BMC Neuroscience.
[6] G. Logroscino,et al. A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease , 2019, Nature Reviews Neurology.
[7] L. Dahan,et al. Early disruption of parvalbumin expression and perineuronal nets in the hippocampus of the Tg2576 mouse model of Alzheimer's disease can be rescued by enriched environment , 2018, Neurobiology of Aging.
[8] F. Cacucci,et al. Effects of rising amyloidβ levels on hippocampal synaptic transmission, microglial response and cognition in APPSwe/PSEN1M146V transgenic mice , 2018, bioRxiv.
[9] Jürgen Götz,et al. Rodent models for Alzheimer disease , 2018, Nature Reviews Neuroscience.
[10] T. Freund,et al. Co-transmission of acetylcholine and GABA regulates hippocampal states , 2018, Nature Communications.
[11] C. Steinhäuser,et al. Plaque‐dependent morphological and electrophysiological heterogeneity of microglia in an Alzheimer's disease mouse model , 2018, Glia.
[12] S. Makin. The amyloid hypothesis on trial , 2018, Nature.
[13] K. Fukunaga,et al. The Disease-modifying Drug Candidate, SAK3 Improves Cognitive Impairment and Inhibits Amyloid beta Deposition in App Knock-in Mice , 2018, Neuroscience.
[14] L. Paninski,et al. Anxiety Cells in a Hippocampal-Hypothalamic Circuit , 2018, Neuron.
[15] E. Galea,et al. Phagocytic clearance of presynaptic dystrophies by reactive astrocytes in Alzheimer's disease , 2017, Glia.
[16] Jason C. Wester,et al. Hippocampal GABAergic Inhibitory Interneurons. , 2017, Physiological reviews.
[17] B. Winblad,et al. APP mouse models for Alzheimer's disease preclinical studies , 2017, The EMBO journal.
[18] T. Brüning,et al. Expression of endogenous mouse APP modulates β-amyloid deposition in hAPP-transgenic mice , 2017, Acta neuropathologica communications.
[19] K. Vossel,et al. Epileptic activity in Alzheimer's disease: causes and clinical relevance , 2017, The Lancet Neurology.
[20] J. DeFelipe,et al. High plasticity of axonal pathology in Alzheimer’s disease mouse models , 2017, Acta neuropathologica communications.
[21] L. Mucke,et al. Network abnormalities and interneuron dysfunction in Alzheimer disease , 2016, Nature Reviews Neuroscience.
[22] S. Itohara,et al. Cognitive deficits in single App knock-in mouse models , 2016, Neurobiology of Learning and Memory.
[23] H. Okano,et al. Modeling neurological diseases with induced pluripotent cells reprogrammed from immortalized lymphoblastoid cell lines , 2016, Molecular Brain.
[24] C. Brayne,et al. Microglial immunophenotype in dementia with Alzheimer’s pathology , 2016, Journal of Neuroinflammation.
[25] Mohan Giri,et al. Genes associated with Alzheimer’s disease: an overview and current status , 2016, Clinical interventions in aging.
[26] Takaomi C. Saido,et al. Familial Alzheimer’s Disease Mutations in Presenilin Generate Amyloidogenic Aβ Peptide Seeds , 2016, Neuron.
[27] U. Sengupta,et al. The Role of Amyloid-β Oligomers in Toxicity, Propagation, and Immunotherapy , 2016, EBioMedicine.
[28] Alzheimer’s Association,et al. 2016 Alzheimer's disease facts and figures , 2016, Alzheimer's & Dementia.
[29] J. Hardy,et al. The amyloid hypothesis of Alzheimer's disease at 25 years , 2016, EMBO molecular medicine.
[30] D. Nicholson,et al. Presynaptic dystrophic neurites surrounding amyloid plaques are sites of microtubule disruption, BACE1 elevation, and increased Aβ generation in Alzheimer’s disease , 2016, Acta Neuropathologica.
[31] C. Jack,et al. Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria , 2016, Alzheimer's & Dementia.
[32] Eric Karran,et al. The Cellular Phase of Alzheimer’s Disease , 2016, Cell.
[33] J. Hardy,et al. Microglial genes regulating neuroinflammation in the progression of Alzheimer's disease , 2016, Current Opinion in Neurobiology.
[34] H. Shoji,et al. Age-related changes in behavior in C57BL/6J mice from young adulthood to middle age , 2016, Molecular Brain.
[35] Angela Yan,et al. Non-alcoholic fatty liver disease induces signs of Alzheimer’s disease (AD) in wild-type mice and accelerates pathological signs of AD in an AD model , 2016, Journal of Neuroinflammation.
[36] M. Owen,et al. Alzheimer's disease: The amyloid hypothesis on trial , 2016, British Journal of Psychiatry.
[37] E. Verdaguer,et al. Vulnerability of calbindin, calretinin and parvalbumin in a transgenic/knock-in APPswe/PS1dE9 mouse model of Alzheimer disease together with disruption of hippocampal neurogenesis , 2015, Experimental Gerontology.
[38] Sagar H. Barage,et al. Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease , 2015, Neuropeptides.
[39] F. Edwards,et al. First effects of rising amyloid-β in transgenic mouse brain: synaptic transmission and gene expression , 2015, Brain : a journal of neurology.
[40] R. Quirion,et al. Regional and sub-regional differences in hippocampal GABAergic neuronal vulnerability in the TgCRND8 mouse model of Alzheimer's disease , 2015, Front. Aging Neurosci..
[41] Jonathan K. Foster,et al. Bone mineral density, adiposity, and cognitive functions , 2015, Front. Aging Neurosci..
[42] M. Cordeiro,et al. Retinal manifestations of Alzheimer's disease. , 2014, Neurodegenerative disease management.
[43] Peter Jonas,et al. Fast-spiking, parvalbumin+ GABAergic interneurons: From cellular design to microcircuit function , 2014, Science.
[44] T. Saido,et al. New mouse model of Alzheimer's. , 2014, ACS chemical neuroscience.
[45] Radouil Tzekov,et al. Vision function abnormalities in Alzheimer disease. , 2014, Survey of ophthalmology.
[46] S. Itohara,et al. Single App knock-in mouse models of Alzheimer's disease , 2014, Nature Neuroscience.
[47] F. Schmitt,et al. Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models , 2014, Front. Genet..
[48] E. Siemers,et al. Amyloid-ß-directed immunotherapy for Alzheimer's disease , 2014, Journal of internal medicine.
[49] T. Freund,et al. Quantitative ultrastructural analysis of basket and axo-axonic cell terminals in the mouse hippocampus , 2014, Brain Structure and Function.
[50] J. Pérez-Ortín,et al. Cytoplasmic 5′-3′ exonuclease Xrn1p is also a genome-wide transcription factor in yeast , 2013, Front. Genet..
[51] C. Holmes,et al. Inflammatory components in human Alzheimer's disease and after active amyloid-β42 immunization. , 2013, Brain : a journal of neurology.
[52] George S. B. Williams,et al. Mitochondrial calcium uptake , 2013, Proceedings of the National Academy of Sciences.
[53] J. Growdon,et al. Differential relationships of reactive astrocytes and microglia to fibrillar amyloid deposits in Alzheimer disease. , 2013, Journal of neuropathology and experimental neurology.
[54] A. Peters,et al. A website entitled “The fine structure of the aging brain” , 2013, The Journal of comparative neurology.
[55] C. Rowe,et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study , 2013, The Lancet Neurology.
[56] K. Mullane,et al. Alzheimer's therapeutics: continued clinical failures question the validity of the amyloid hypothesis-but what lies beyond? , 2013, Biochemical pharmacology.
[57] J. Nordenström. The calcium connection , 2013 .
[58] A. Wimo,et al. The global prevalence of dementia: A systematic review and metaanalysis , 2013, Alzheimer's & Dementia.
[59] G. Paxinos,et al. Paxinos and Franklin's the Mouse Brain in Stereotaxic Coordinates , 2012 .
[60] R. Tanzi. The genetics of Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.
[61] Johannes E. Schindelin,et al. TrakEM2 Software for Neural Circuit Reconstruction , 2012, PloS one.
[62] R. Miledi,et al. Loss of functional GABAA receptors in the Alzheimer diseased brain , 2012, Proceedings of the National Academy of Sciences.
[63] Masahiko Watanabe,et al. Release probability of hippocampal glutamatergic terminals scales with the size of the active zone , 2012, Nature Neuroscience.
[64] Daniel Friedman,et al. Seizures and Epilepsy in Alzheimer's Disease , 2012, CNS neuroscience & therapeutics.
[65] L. Mucke,et al. Alzheimer Mechanisms and Therapeutic Strategies , 2012, Cell.
[66] J. Fadel,et al. Interneuron loss reduces dendritic inhibition and GABA release in hippocampus of aged rats , 2012, Neurobiology of Aging.
[67] P. Jonas,et al. How the 'slow' Ca2+ buffer parvalbumin affects transmitter release in nanodomain-coupling regimes , 2011, Nature Neuroscience.
[68] Antonia Gutierrez,et al. Abnormal accumulation of autophagic vesicles correlates with axonal and synaptic pathology in young Alzheimer’s mice hippocampus , 2011, Acta Neuropathologica.
[69] Chengjie Xiong,et al. Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease , 2011, Alzheimer's Research & Therapy.
[70] R. Tsien,et al. Enhancing Serial Block-Face Scanning Electron Microscopy to Enable High Resolution 3-D Nanohistology of Cells and Tissues , 2010 .
[71] T. Pozzan,et al. Mitochondria: the calcium connection. , 2010, Biochimica et biophysica acta.
[72] P. Hof,et al. Hippocampal interneuron loss in an APP/PS1 double mutant mouse and in Alzheimer’s disease , 2010, Brain Structure and Function.
[73] M. D'Andrea,et al. Morphologically distinct types of amyloid plaques point the way to a better understanding of Alzheimer’s disease pathogenesis , 2010, Biotechnic & histochemistry : official publication of the Biological Stain Commission.
[74] Lee L Yu,et al. Characterization of SiGe Films for Use as a National Institute of Standards and Technology Microanalysis Reference Material (RM 8905) , 2009, Microscopy and Microanalysis.
[75] Henry Brodaty,et al. Threat perception in mild cognitive impairment and early dementia. , 2009, The journals of gerontology. Series B, Psychological sciences and social sciences.
[76] K. Green. Calcium in the initiation, progression and as an effector of Alzheimer’s disease pathology , 2009, Journal of cellular and molecular medicine.
[77] Marie-Claude Potier,et al. Classification and basic pathology of Alzheimer disease , 2009, Acta Neuropathologica.
[78] Jeffrey A. James,et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. , 2008, Archives of neurology.
[79] M. Caballero-Bleda,et al. Subfield and layer-specific depletion in calbindin-D28K, calretinin and parvalbumin immunoreactivity in the dentate gyrus of amyloid precursor protein/presenilin 1 transgenic mice , 2008, Neuroscience.
[80] C. Geula,et al. Cholinergic Neuronal and Axonal Abnormalities Are Present Early in Aging and in Alzheimer Disease , 2008, Journal of neuropathology and experimental neurology.
[81] M. Beal,et al. Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. , 2008, Trends in molecular medicine.
[82] Anatol C. Kreitzer,et al. Aberrant Excitatory Neuronal Activity and Compensatory Remodeling of Inhibitory Hippocampal Circuits in Mouse Models of Alzheimer's Disease , 2007, Neuron.
[83] Pablo Fuentealba,et al. Cell Type-Specific Tuning of Hippocampal Interneuron Firing during Gamma Oscillations In Vivo , 2007, The Journal of Neuroscience.
[84] D. Ulrich,et al. GABAB receptors: synaptic functions and mechanisms of diversity , 2007, Current Opinion in Neurobiology.
[85] J. F. López-Téllez,et al. Early neuropathology of somatostatin/NPY GABAergic cells in the hippocampus of a PS1×APP transgenic model of Alzheimer's disease , 2006, Neurobiology of Aging.
[86] J. Schneider,et al. Neuropathology of older persons without cognitive impairment from two community-based studies , 2006, Neurology.
[87] György Buzsáki,et al. Populations of hippocampal inhibitory neurons express different levels of cytochrome c , 2006, The European journal of neuroscience.
[88] Jozsef Csicsvari,et al. Complementary Roles of Cholecystokinin- and Parvalbumin-Expressing GABAergic Neurons in Hippocampal Network Oscillations , 2005, The Journal of Neuroscience.
[89] M. Schwartz,et al. Activation of microglia by aggregated β-amyloid or lipopolysaccharide impairs MHC-II expression and renders them cytotoxic whereas IFN-γ and IL-4 render them protective , 2005, Molecular and Cellular Neuroscience.
[90] W. Streit. Microglia and neuroprotection: implications for Alzheimer's disease , 2005, Brain Research Reviews.
[91] M. L. de Ceballos,et al. Prevention of Alzheimer's Disease Pathology by Cannabinoids: Neuroprotection Mediated by Blockade of Microglial Activation , 2005, The Journal of Neuroscience.
[92] P. Riederer,et al. Perineuronal nets potentially protect against oxidative stress , 2004, Experimental Neurology.
[93] T. Kosaka,et al. Immunocytochemical characterization of hippocamposeptal projecting GABAergic nonprincipal neurons in the mouse brain: a retrograde labeling study , 2002, Brain Research.
[94] G. Buzsáki. Theta Oscillations in the Hippocampus , 2002, Neuron.
[95] J. Hardy,et al. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease , 2000, Nature.
[96] Ralph A. Nixon,et al. Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease , 2000, Nature.
[97] Z. Henderson,et al. Perineuronal nets ensheath fast spiking, parvalbumin‐immunoreactive neurons in the medial septum/diagonal band complex , 2000, The European journal of neuroscience.
[98] M. Frotscher,et al. Cerebral Amyloid Induces Aberrant Axonal Sprouting and Ectopic Terminal Formation in Amyloid Precursor Protein Transgenic Mice , 1999, The Journal of Neuroscience.
[99] R. Motter,et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.
[100] L. Acsády,et al. Postsynaptic targets of somatostatin-immunoreactive interneurons in the rat hippocampus , 1999, Neuroscience.
[101] G. Buzsáki,et al. Interneurons of the hippocampus , 1998, Hippocampus.
[102] E. Mufson,et al. Parvalbumin-immunoreactive neurons in the hippocampal formation of Alzheimer's diseased brain , 1997, Neuroscience.
[103] R. Mrak,et al. Neuritic plaque evolution in Alzheimer’s disease is accompanied by transition of activated microglia from primed to enlarged to phagocytic forms , 1997, Acta Neuropathologica.
[104] John Hardy,et al. Amyloid, the presenilins and Alzheimer's disease , 1997, Trends in Neurosciences.
[105] T. Freund,et al. Differences between Somatic and Dendritic Inhibition in the Hippocampus , 1996, Neuron.
[106] Carl W. Cotman,et al. Identification and distribution of axonal dystrophic neurites in Alzheimer's disease , 1993, Brain Research.
[107] W. Benzing,et al. Substance P and somatostatin coexist within neuritic plaques: Implications for the pathogenesis of Alzheimer's disease , 1989, Neuroscience.
[108] R. Katzman.,et al. Clinical, pathological, and neurochemical changes in dementia: A subgroup with preserved mental status and numerous neocortical plaques , 1988, Annals of neurology.
[109] F. Bloom,et al. Somatostatin immunoreactivity in neuritic plaques of Alzheimer's patients , 1985, Nature.
[110] P. Somogyi,et al. A new type of specific interneuron in the monkey hippocampus forming synapses exclusively with the axon initial segments of pyramidal cells , 1983, Brain Research.
[111] M. Wong-Riley,et al. Histochemical localization of cytochrome oxidase in the hippocampus: Correlation with specific neuronal types and afferent pathways , 1982, Neuroscience.
[112] M. Abercrombie. Estimation of nuclear population from microtome sections , 1946, The Anatomical record.
[113] J. Zaia,et al. Extracellular matrix proteomics in schizophrenia and Alzheimer’s disease , 2016, Analytical and Bioanalytical Chemistry.
[114] K. Hensley. Neuroinflammation in Alzheimer's disease: mechanisms, pathologic consequences, and potential for therapeutic manipulation. , 2010, Journal of Alzheimer's disease : JAD.
[115] M. Caballero-Bleda,et al. SUBFIELD AND LAYER-SPECIFIC DEPLETION IN CALBINDIN-D28K, CALRETININ AND PARVALBUMIN IMMUNOREACTIVITY IN THE DENTATE GYRUS OF APP/PS1 TRANSGENIC MICE , 2008 .
[116] P. Somogyi,et al. Defined types of cortical interneurone structure space and spike timing in the hippocampus , 2005, The Journal of physiology.
[117] P. Somogyi,et al. Spike timing of dendrite-targeting bistratified cells during hippocampal network oscillations in vivo , 2004, Nature Neuroscience.
[118] P. Somogyi,et al. Properties of horizontal axo‐axonic cells in stratum oriens of the hippocampal CA1 area of rats in vitro , 2004, Hippocampus.
[119] B. Hyman,et al. Microglial response to amyloid plaques in APPsw transgenic mice. , 1998, The American journal of pathology.